At a glance
- Originator Pfizer
- Class Antihypertensives; Ischaemic heart disorder therapies
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Angina pectoris
Most Recent Events
- 29 Aug 1995 Discontinued-Preclinical for Angina pectoris in United Kingdom (Unknown route)